As continuous glucose monitors have improved in quality and spread through the diabetes marketplace in recent years, their status has gone from expensive curiosity to must-have treatment tool.

But new developments in the space show that there’s a lot of room for growth and refinement.

Take the Eversense, an entirely new approach to the CGM concept from Senseonics. It’s an implantable device, which is inserted into the upper arm by a doctor every 90 days. When coupled with a transmitter and mobile app, could the EverSense change how diabetics approach CGM technology? Sure, the doctor’s visit might be a hassle, but it might be worth avoiding the trickiness and irritation of patients inserting sensors weekly.

FreeStyle also wants in on the game with its Libre devices, which are sensors worn on the upper arm for 10 or 14 days, depending on type. A blood glucose number is obtained by passing a handheld reader over the sensor for an instant result. A cheaper option than traditional CGMs, the Libre doesn’t yet offer Bluetooth integration, although its second generation — going on sale in Europe soon — does.

Dexcom has also been upping its game with the G6 line. It features an improved sensor applicator, 10-day wear time (up from the previous week) and is “FDA-permitted to make diabetes treatment decisions without confirmatory fingersticks or calibration.” With this attractive combination of features, long-term use of Dexcom sensors will become easier and more convenient than ever.

Medtronic’s efforts in the space have been focused largely on the integration of their Guardian CGM into the MiniMed 670G closed loop system.

When first introduced, CGMs clearly had the most applicability to the lives of type 1 diabetics, whose daily routines depend on having constant, accurate blood glucose readings. But the efforts of EverSense and FreeStyle suggest an expansion of the market into those with type 2 diabetes, who might not be as motivated to constantly and consistently use the technology, but would nevertheless benefit from having the information.

And with other closed-loop systems making their slow yet steady way toward the marketplace, it’s clear that CGMs will continue to play big roles in the lives of more and more diabetics in years to come.